Genetix Biotherapeutics at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Genetix Biotherapeutics brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 3653. Its program centres on gene therapy for sickle cell disease. It hosts a session linking clinical outcomes to the patient journey and supports a symposium on new sickle cell options.
| Organization | ASH 2026 Attendance |
|---|---|
Genetix Biotherapeutics Somerville, MA | |
Privately held company with FDA-approved gene therapies for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy. | Booth Exhibiting at Booth 3653 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. Talk Sun Dec 13 8:00am–9:00am |
Find decision makers at Genetix Biotherapeutics
Tell us what you sell and we’ll find the people at Genetix Biotherapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction